| pubmed-article:7492921 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7492921 | lifeskim:mentions | umls-concept:C0206193 | lld:lifeskim |
| pubmed-article:7492921 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:7492921 | lifeskim:mentions | umls-concept:C0029162 | lld:lifeskim |
| pubmed-article:7492921 | lifeskim:mentions | umls-concept:C0023449 | lld:lifeskim |
| pubmed-article:7492921 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:7492921 | lifeskim:mentions | umls-concept:C0695347 | lld:lifeskim |
| pubmed-article:7492921 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:7492921 | pubmed:dateCreated | 1996-1-11 | lld:pubmed |
| pubmed-article:7492921 | pubmed:abstractText | Sixty-eight children who were diagnosed with acute lymphoblastic leukaemia (ALL) prior to age 5 years and treated with chemotherapy alone, chemotherapy plus 1800 cGy cranial irradiation (RT), or chemotherapy plus 2400 cGy RT were assessed clinically for overall dental health. All patients were at least 60 months in continuous remission. Dental caries were assessed by NIDR diagnostic criteria, oral hygiene was assessed by the modified Oral Hygiene Index, and gingival health was assessed by the modified gingival index of Loe and Silness. There was no significant difference in caries experience between the three groups nor with the normal population. Those patients that received 2400 cGy RT had significantly higher plaque and periodontal index scores than patients in the other treatment groups. The results of this study suggest that: (1) children with ALL treated with any of the described modalities are at no greater risk of developing dental caries than the normal population; and (2) patients receiving 2400 cGy prior to age 5 years are at greater risk of developing periodontal disease than patients treated with other central nervous system prophylaxis regimens examined in this study. | lld:pubmed |
| pubmed-article:7492921 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7492921 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7492921 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7492921 | pubmed:citationSubset | D | lld:pubmed |
| pubmed-article:7492921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7492921 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7492921 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:7492921 | pubmed:issn | 0964-1955 | lld:pubmed |
| pubmed-article:7492921 | pubmed:author | pubmed-author:SonisA LAL | lld:pubmed |
| pubmed-article:7492921 | pubmed:author | pubmed-author:SallanSS | lld:pubmed |
| pubmed-article:7492921 | pubmed:author | pubmed-author:WaberD PDP | lld:pubmed |
| pubmed-article:7492921 | pubmed:author | pubmed-author:TarbellN JNJ | lld:pubmed |
| pubmed-article:7492921 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7492921 | pubmed:volume | 31B | lld:pubmed |
| pubmed-article:7492921 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7492921 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7492921 | pubmed:pagination | 250-2 | lld:pubmed |
| pubmed-article:7492921 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:7492921 | pubmed:meshHeading | pubmed-meshheading:7492921-... | lld:pubmed |
| pubmed-article:7492921 | pubmed:meshHeading | pubmed-meshheading:7492921-... | lld:pubmed |
| pubmed-article:7492921 | pubmed:meshHeading | pubmed-meshheading:7492921-... | lld:pubmed |
| pubmed-article:7492921 | pubmed:meshHeading | pubmed-meshheading:7492921-... | lld:pubmed |
| pubmed-article:7492921 | pubmed:meshHeading | pubmed-meshheading:7492921-... | lld:pubmed |
| pubmed-article:7492921 | pubmed:meshHeading | pubmed-meshheading:7492921-... | lld:pubmed |
| pubmed-article:7492921 | pubmed:meshHeading | pubmed-meshheading:7492921-... | lld:pubmed |
| pubmed-article:7492921 | pubmed:meshHeading | pubmed-meshheading:7492921-... | lld:pubmed |
| pubmed-article:7492921 | pubmed:meshHeading | pubmed-meshheading:7492921-... | lld:pubmed |
| pubmed-article:7492921 | pubmed:meshHeading | pubmed-meshheading:7492921-... | lld:pubmed |
| pubmed-article:7492921 | pubmed:meshHeading | pubmed-meshheading:7492921-... | lld:pubmed |
| pubmed-article:7492921 | pubmed:meshHeading | pubmed-meshheading:7492921-... | lld:pubmed |
| pubmed-article:7492921 | pubmed:meshHeading | pubmed-meshheading:7492921-... | lld:pubmed |
| pubmed-article:7492921 | pubmed:meshHeading | pubmed-meshheading:7492921-... | lld:pubmed |
| pubmed-article:7492921 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7492921 | pubmed:articleTitle | The oral health of long-term survivors of acute lymphoblastic leukaemia: a comparison of three treatment modalities. | lld:pubmed |
| pubmed-article:7492921 | pubmed:affiliation | Children's Hospital, Boston, Massachusetts, USA. | lld:pubmed |
| pubmed-article:7492921 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7492921 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:7492921 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7492921 | lld:pubmed |
